Year: 2022
Type: review
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to regulating LDL-R, PCSK9 inhibitors can also bind Toll-like receptors (TLRs), scavenger receptor B (SR-B/CD36), low-density lipoprotein receptor-related protein 1 (LRP1), apolipoprotein E receptor-2 (ApoER2) and very-low-density lipoprotein receptor (VLDL-R) reducing the lipoprotein concentration and slowing thrombosis. In addition to cardiovascular diseases, PCSK9 is also used in pancreatic cancer, sepsis, and Parkinson's disease. Currently marketed PCSK9 inhibitors include alirocumab, evolocumab, and inclisiran, as well as small molecules, nucleic acid drugs, and vaccines under development. This review systematically summarized the application, preclinical studies, safety, mechanism of action, and latest research progress of PCSK9 inhibitors, aiming to provide ideas for the drug research and development and the clinical application of PCSK9 in cardiovascular diseases and expand its application in other diseases.
Source: Cells
Authors: Chunping Liu(Conceptualization, Writing – original draft, Writing – review & editing), Jing Chen(Writing – original draft, Writing – review & editing), Huiqi Chen(Writing – original draft), Tong Zhang(Writing – review & editing), Dongyue He(Visualization, Writing – original draft), Qiyuan Luo(Visualization, Writing – original draft), Jiaxin Chi(Writing – original draft), Zebin Hong(Writing – original draft), Yizhong Liao(Writing – original draft), Shihui Zhang(Writing – original draft), Qizhe Wu(Writing – original draft), Huan Cen(Writing – original draft), Guangzhong Chen(Writing – original draft), Jinxin Li(Writing – original draft), Lei Wang(Conceptualization, Supervision)
Institutions: Guangzhou University of Chinese Medicine, University of Macau, Guangdong Provincial Hospital of Chinese Medicine, Wuyi University, Wuyi University, Shenzhen University, Shenzhen University Health Science Center, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,303
Awards: G1801830072, G1802412060, G1885602140, G2587937449, G2882147989, G3053452418, G3762290345, G3782973710, G4012602644, G5182472371, G5560806066, G5677091812, G5976470427, G6038661045, G6203805480, G6262613662, G6783203029, G6844411428, G6922602626, G6957635824, G7182365489, G739821196, G7497629743, G7835099912, G8007435544, G809691361, G8489251091, G8936663112
OpenAlex ID: W4297149256
